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Background: HIV and tuberculosis are frequently diagnosed concurrently. In March 2021, World Health Organization recom-
mended that antiretroviral therapy (ART) should be started within two weeks of tuberculosis treatment start, at any CD4
count. We assessed whether earlier ART improved outcomes in people with newly diagnosed HIV and tuberculosis.
Methods: We did a systematic review by searching nine databases for trials that compared earlier ART to later ART initiation
in people with HIV and tuberculosis. We included studies published from database inception to 12 March 2021. We compared
ART within four weeks versus ART more than four weeks after TB treatment, and ART within two weeks versus ART between
two and eight weeks, and stratified analysis by CD4 count. The main outcome was death; secondary outcomes included IRIS
and AIDS-defining events. We pooled effect estimates using random effects meta-analysis.
Results and discussion: We screened 2468 abstracts, and identified nine trials. Among people with all CD4 counts, there was
no difference in mortality by earlier ART (≤4 week) versus later ART (>4 week) (risk difference [RD] 0%, 95% confidence interval
[CI] 2% to +1%). Among people with CD4 count ≤50 cells/mm3, earlier ART (≤4 weeks) reduced risk of death (RD 6%,
10% to 1%). Among people with all CD4 counts earlier ART (≤4 weeks) increased the risk of IRIS (RD +6%, 95% CI +2% to
+10%) and reduced the incidence of AIDS-defining events (RD 2%, 95% CI 4% to 0%). Results were similar when trials were
restricted to the four trials which permitted comparison of ART within two weeks to ART between two and eight weeks. Trials
were conducted between 2004 and 2014, before recommendations to treat HIV at any CD4 count or to rapidly start ART in
people without TB. No trials included children or pregnant women. No trials included integrase inhibitors in ART regimens.
Discussion: Earlier ART did not alter risk of death overall among people living with HIV who had TB disease. For logistical
and patient preference reasons, earlier ART initiation for everyone with TB and HIV may be preferred to later ART.
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1 | INTRODUCTION
Tuberculosis (TB) is the most important cause of morbidity and
mortality among people living with HIV (PLHIV) globally [1,2].
All people with TB should be offered testing for HIV and every-
one newly diagnosed with HIV should have TB screening,
meaning that TB and HIV are often diagnosed simultaneously.
The potential risks of starting antiretrovial therapy (ART)
early in TB treatment may include drug toxicity, drug–drug
interactions [3], a perceived high pill burden for patients and
immune reconstitution inflammatory syndrome (IRIS) [4,5], all
of which may affect adherence and retention in care [6]. The
benefits of starting ART early in TB treatment may include
reduced HIV complications (including progression to AIDS-
defining illness and death) [7,8] and shorter time to HIV viral
load suppression, which has benefits for patients and their
partners through reduced HIV transmission [9]. Early ART ini-
tiation may also simplify programme implementation and avoid
unintended delays due to pending CD4 count results and
more complex differentiated pathways [10].
In March 2021, World Health Organization recommended
that antiretroviral therapy (ART) should be started within two
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weeks of tuberculosis treatment start, at any CD4 count [11].
The previous (2016) WHO recommendations [12] were that
people with CD4 < 50 cells/mm3 should start ART within two
weeks and others to start ART within eight weeks. The old
2016 recommendation may have caused logistical complexity,
particularly in situations where CD4 cell counts are not read-
ily available. Furthermore, since 2017 rapid ART (within seven
days of HIV diagnosis) has been recommended for most
PLHIV without TB, as evidence suggests that reducing delay
between diagnosis of HIV and starting ART improves out-
comes [13,14]. The old 2016 recommendation was produced
before much of the evidence for rapid ART in people with
HIV without TB. Prior to the March 2021 WHO guidelines, at
least three high HIV burden countries (Malawi, Zambia and
Uganda) had already issued national guidelines recommending
ART within or at two weeks after starting TB treatment for
people with TB and HIV at all CD4 cell counts [15-17].
In light of high levels of mortality associated with HIV
and TB coinfection, and the trend towards earlier initiation
of ART in PLHIV without TB, we sought to review the evi-
dence around the timing of ART initiation PLHIV who have
TB disease. This systematic review was conducted before
the March 2021 updated guidelines were issued; this work
was part of the evidence considered by the guideline devel-
opment group.
2 | METHODS
2.1 | Inclusion and exclusion criteria
We systematically reviewed studies that compared different
time-points of ART initiation in PLHIV who were not already
on ART and who were initiating TB treatment. We included
studies of PLHIV of any age, in any country setting. We
included two sets of interventions and comparators. First, we
compared starting ART within two weeks to starting ART
between two and eight weeks after TB treatment as these
are the two strategies recommended in 2016 WHO guidance
(Comparison A). However, we included a comparison with a
more general definition (Comparison B) because some trials
used different time intervals to define early and delayed ART
initiation (e.g. compared four weeks to twelve weeks). We
analysed data across all CD4 cell counts, and by CD4 cell
count strata using a cut-point of CD4 count 50 cells/mm3 to
reflect 2016 WHO guidelines. These categorisations were
pre-specified. The main outcome of interest was mortality;
secondary outcomes included incidence of IRIS, AIDS-defining
events, serious adverse events (SAEs), viral load suppression
and loss to follow-up.
We only included randomized trials and we excluded trials
that were solely conducted among people with TB meningitis,
as TB meningitis is managed substantially differently from pul-
monary TB (e.g. steroids are routinely used, patients would
usually be hospital inpatients), and the risks associated with
IRIS may be higher [18].
2.2 | Search strategy and data extraction
The protocol and search strategy are available online at
PROSPERO (CRD42020190396). We used a broad search
strategy to identify randomized controlled trials that
compared the timing of ART in people with HIV and TB. The
search was designed with the assistance of a specialist librar-
ian. We searched eight databases including Medline and
Embase and two clinical trial registries for articles published
between database inception and 12 March 2020
(Appendix S1).
All titles and abstracts were reviewed by RMB and HMR
using the Rayaan software program [19]. After reviewing an
initial 10% sample of titles/abstracts in duplicate, and deter-
mining that there was 100% agreement between reviewers,
the remainder of title abstracts were reviewed by one
reviewer only. All papers at full-text review stage were
reviewed by both RMB and HMR for decision on inclusion.
Both RMB and HMR extracted data independently in dupli-
cate from studies selected for inclusion. Data were extracted
from published manuscripts, supplementary data files and
study protocols and entered into a spreadsheet. Where CD4
cell count-disaggregated data were not available, we contacted
authors.
2.3 | Statistical methods and risk of bias
assessment
Data were pooled in meta-analysis using package “meta” [20]
in R [21]. We expressed effects as absolute risk differences.
Random effects meta-analysis was used because we antici-
pated heterogeneity in results between studies. We used the
Mantel–Haenszel method to estimate confidence intervals (CI)
of risk differences, and the DerSimonian Laird method to esti-
mate variance of pooled effect [22]. We used an intention-to-
treat approach and included all randomized participants in the
denominator with the exception of one study, which reported
outcomes for a pre-specified modified intention-to-treat popu-
lation where participants whose sputum samples were culture
negative for Mycobacterium tuberculosis were excluded after
randomization [23]. For the HIV viral suppression outcome,
the denominator was the number of people with HIV viral
load measured.
We used the Cochrane Risk of Bias 2 tool [24] to assess
study quality. Risk of bias assessments were performed in
duplicate by HMR and RMB and differences were resolved by
consensus and discussion with PM. PRISMA guidelines were
used for reporting (checklist in Appendix S2).
3 | RESULTS AND DISCUSSION
After removing duplicates, we identified 2468 articles, of
which 10 were included in our quantitative synthesis and
meta-analysis (Figure 1). We identified nine studies that com-
pared the effects of earlier to later ART initiation among
PLHIV and TB disease, comprised of 10 manuscripts and one
unpublished paper (identified in the search through an
abstract presented at the IAS Conference 2016). We con-
tacted the authors of the unpublished paper and received data
to permit inclusion. These trials were conducted between June
2004 and December 2014 and included a total of 5030 ran-
domized participants. Five studies were conducted in sub-
Saharan Africa, including two multi-country trials; three were
in Asia, and one study included participants from Africa, Asia,
North America and South America.
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The nine trials had important differences related to patient
population (particularly CD4 count inclusion criteria), definitions
of TB (whether people with probable TB, or with extrapul-
monary TB were included) and timing of ART (Table 1). Four of
the nine trials included participants with clinically diagnosed TB
(i.e. TB diagnosed without microbiological confirmation) [25-28].
Three studies restricted participation to those with pulmonary
TB only [23,29], whereas six trials included participants with
pulmonary and extrapulmonary TB [25,26,27,28,30,31]. No tri-
als included children under 13 years of age: two trials included
both adults and adolescents (age ≥13 years) [26,30] and the
remaining seven included adults (≥18 years) only.
Four trials permitted comparison between starting ART within
or at two weeks versus starting ART at between two and eight
weeks (the two timepoints in the 2016 WHO recommendation,
Comparison A) [25,30,31]. The remaining trials used different
timepoints and permitted a comparison between ART ≤4 versus
>4 weeks (Comparison B). One trial (Amogne et al.) randomized
people to three arms (ARTwithin one, four and eight weeks) [25];
for Comparison A meta-analyses, the four- and eight-week
groups are combined into “later ART”, whereas for Comparisons
B meta-analyses the one- and four-week groups are combined as
“earlier ART” in accordance with our protocol.
Trials had slightly different definitions of endpoints (espe-
cially with regards to definitions of serious adverse events),
and these are summarized in Table S1. Six included trials were
at low risk of bias for the primary outcome of death
(Figure 2). We had some concerns of bias for two trials
related to high proportions of loss to follow-up, and high
concern of bias in one trial due to very high loss to follow-up
which was different between arms.
3.1 | Mortality
Overall, weighted mean mortality among all people random-
ized after one year was 8.6% (Table 2, range 2.9% in
TB-HAART study to 17% in CAMELIA study).
In the four studies that permitted a comparison of starting
ART ≤2 weeks versus two to eight weeks (Comparison A), two
studies showed fewer deaths in those starting ART at two
weeks (CAMELIA [31] and RAFA, personal communication),
whereas two showed more deaths (Amogne et. al. [25] and
THIRST [30]). All 95% CIs included zero (i.e. null effect). The I2
value was 55%, indicating moderate heterogeneity (Figure 3).
We estimate an overall effect from our random-effects model of
a risk difference (RD) of 1% (95% CI 6% to +4%).
In nine studies included in Comparison B (≤4 vs. >4 weeks)
the absolute risk difference (RD) for mortality for earlier ART
(≤4 weeks) compared to later ART (>4 weeks) was 0% (95%
CI 2% to +1%, I2 = 0%).
Among participants with CD4 counts ≤50 cells/mm3, two
trials permitted a comparison of starting ART within two
weeks versus between two and eight weeks and had data dis-
aggregated by CD4 count. Amogne et al. showed a slightly
greater proportion of deaths among people starting ART ear-
lier (with a very wide confidence interval, RD +4%, 95% CI
11% to +18%), and CAMELIA showed fewer deaths with
earlier ART (5%, 95% CI 12% to +2%). Meta-analysis of
Database search (12 March 2020)
n = 2468 records
Records screened
n = 2468
Records excluded on screening
n = 2267




-Not an RCT (118)
-Not relevant popula on [i.e. not PLHIV star ng TB treatment] (20)
Not all star ng TB treatment (15), not all HIV-posi ve (2), 
only TB meningi s (3 papers, 1 study)
-Not a trial of earlier vs. later ART (26)
Primary systems interven ons (9), TB diagnos c 
interven on (3), TB treatment regimen interven on (1), ART 
regimen interven on (7), various adjuvant therapies (2), 
ART ini a on not corresponding to PICO [ART during TB 
treatment then stopping] (4 papers, 1 study)
- Secondary papers related to included studies (25)
- Trial registra on for a study that never started or never completed (2)
Studies included in quan ta ve 
synthesis
(n = 9 studies, 10 papers)
Figure 1. PRISMA diagram. PLHIV, people living with HIV; RCT, randomized controlled trial; TB, tuberculosis.
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these two trials gave a combined absolute risk difference of
3% (95% CI 10% to +4%, I2 = 8%). Three further trials
(STRIDE, SAPiT and TIME) disaggregated data by CD4 cell
count strata and used timepoints of four weeks versus eight
to twelve or twelve weeks; all of these studies reported fewer
deaths in groups with earlier ART in those with low CD4
counts, giving a comparison B (≤4 weeks vs. >4 weeks) RD
6% (five studies, 95% CI 10% to 1%, I2 = 0%).
Among participants with higher CD4 counts (>50 cells/
mm3), Amogne et al. found a greater number of deaths in
those started on ART within two weeks compared to within
eight weeks. The RAFA trial and CAMELIA both showed fewer
deaths in the early ART group. Meta-analysis showed an over-
all risk difference of 2% (95% CI 7% to +4%, I2 = 45%). In
the more general comparison of earlier (≤4 weeks) versus
later ART (>4 weeks) in people with CD4 cell count
>50 cells/mm3, there was no difference in mortality by timing
of ART, with meta-estimate of risk difference +1% (95% CI
2% to +3%, I2 = 23%), Figure 4.
3.2 | IRIS
IRIS occurred in 8.5% of participants (weighted mean, range
0% in THIRST trial to 26% in TIME). Most studies assessed
IRIS by using definitions defined in Meintjes et al. [32]. In the
STRIDE and TB-HAART trials, assessors of IRIS were blinded
to ART assignment and taking ART was not a criterion for
developing IRIS.
IRIS was slightly more common among patients who started
ART within two weeks compared to between two and eight
weeks, but the pooled risk difference failed to reach statistical
significance (four studies, RD +7%, 95% CI 3% to +17%,
I2 = 95%). IRIS was more common among people started on
ART ≤4 weeks compared to >4 weeks (nine studies, RD +6%,
95% CI +2% to +10%, I2 = 85%) (Figure 5). Among people
with CD4 ≤50 cells/mm3, IRIS was more common in people
started on ART ≤4 weeks compared to >4 weeks, (five stud-
ies, +19%, 95% CI +14% to +25%, I2 = 36%). Among patients
with CD4 > 50 cells/mm3, IRIS was slightly more common in
early ART groups (seven studies, RD +3%, 0% to +6%,
I2 = 77%) (Figure in Appendix S3).
3.3 | AIDS-defining events
Overall, 8% of all participants (weighted mean) experienced an
AIDS-defining event during study follow-up (reported in six
studies, range 1% in Sinha et al. to 15% in TIME). There were
slightly fewer AIDS-defining events in people started on ART
≤2 weeks compared to two to eight weeks (two studies, RD
2%, 95% CI 6% to +3%, I2 = 0%) and AIDS-defining
events were slightly less common among people starting ART
at ≤4 weeks compared to >4 weeks (six studies, RD 2%,
95% CI 4% to 0%, I2 = 0%) — Appendix S3.
In the three studies that reported CD4-count disaggregated
data for AIDS-defining events (SAPiT, Amogne et al. and
STRIDE) [25,26,29], earlier ART (≤4 weeks) was associated with
a reduced risk of AIDS-defining events in people with CD4
≤50 cells/mm3 (RD 10%, 95% CI 16% to 3%, I2 = 0%).
3.4 | SAEs
There were considerable differences in how SAEs were
defined, particularly whether IRIS or AIDS-defining events
were also included as SAEs (see Table S1). One study only
reported adverse events related to hepatoxicity [25], six stud-
ies reported numbers of SAEs, two reported numbers of peo-
ple with ≥1 SAE and one study reported both.
Two studies (CAMELIA, TIME) [27,31] reported treatment-
related SAEs, both counting numbers of events (rather than
numbers of people with ≥1 event) and reporting a person-
Figure 2. Risk of bias assessment for death outcome (Cochrane ROB2).
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time denominator, showing similar rates of drug-related SAEs
in earlier versus later ART (Table S2).
3.5 | HIV viral load suppression
Six studies reported HIV viral load suppression (five studies
measured at 12 months, and one study measured at
18 months from randomization). The proportion of partici-
pants with viral load results ranged from 24% (RAFA) to 96%
(THIRST). There was no difference in the proportion of partici-
pants with a suppressed viral load between the earlier ART
(≤4 weeks) intervention versus later ART intervention
(<4 weeks) (RD 0%, 2% to +3%, I2 = 0%) – Appendix S3.
4 | DISCUSSION
Across nine studies with a variety of timepoints and popula-
tions, starting ART earlier (≤4 weeks) compared to later
(>4 weeks) had no significant effect on mortality. Among
PLHIV with CD4 ≤50 cells/mm3, earlier ART reduced mortal-
ity. With higher CD4 counts (>50 cells/mm3), there was prob-
ably no effect of earlier ART on death.
IRIS was slightly more common among people initiating ART
early. It is possible that a (probably small) proportion of this
apparent effect might be related to reduced mortality in early
ART group (as people who have died are no longer at risk of
IRIS). A major limitation for IRIS outcome is that only one trial
was placebo-controlled and seven of the nine trials used
unblinded outcome assessors, which may lead to bias in non-
mortality outcomes (such as IRIS and AIDS-defining events). In
seven of nine studies, by definition, people not on ART could
not develop IRIS, so people in later ART group were “at risk”
of IRIS for a shorter time. One of the two studies in which
assessors were blinded (TB-HAART) reported slightly higher
rates of IRIS in those starting ART later compared to earlier.
The majority of cases of IRIS in all studies were mild or mod-
erate, and IRIS-related deaths were uncommon (although the
cause of death was not ascertained in all studies). Importantly,
the increased risk of IRIS was most marked in those with low
CD4 cell counts, which is also the group in which there was
stronger evidence of overall mortality benefit.
Four studies did not specifically exclude participants with TB
meningitis from their trials (although it is not reported how
many recruited participants actually had TB meningitis) and
separate trial evidence has shown that delayed ART in the
Figure 3. Forest plots showing effect estimates (absolute risk difference) of earlier versus later ART on death (all CD4 counts). Summary
estimates are from random effects meta-regression models, using DerSimonian Laird method to estimate variance.
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setting of TB meningitis is probably beneficial [33], in keeping
with other trials showing benefit from delaying ART for crypto-
coccal meningitis [34]. IRIS is more likely to have serious sequa-
lae in central nervous system TB than in TB at non-central
nervous system sites [18]. There was no significant difference
in AIDS-defining events across the population of people initiat-
ing ART, but those with CD4 cell count <50 cells/mm3 had a
reduced risk of AIDS-defining events with earlier ART.
(A)
(B)
Figure 4. Forest plots showing effect estimates (absolute risk difference) of earlier versus later ART on death (by CD4 count). Summary
estimates are from random effects meta-regression models, using DerSimonian Laird method to estimate variance.
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Since these trials were conceived and conducted, HIV care
in many national programmes has significantly changed. “Treat
all” recommendations, coupled with recommendations for
rapid and same-day ART mean that PLHIV without TB start
on ART much sooner after diagnosis than would have been
the case during the time that most of these trials were being
conducted. ART regimens have also changed substantially
since these studies; many of these studies used zidovudine- or
stavudine-based ART which have higher toxicity and more sev-
ere side effect profiles than newer integrase-inhibitor contain-
ing regimens. Integrase inhibitors have been shown to be safe
and effective treatments for HIV in people who have TB dis-
ease, as demonstrated in two randomized studies (in both of
these studies ART was started around six weeks after TB
treatment initiation) [35,36]. None of the included trials in this
review used integrase inhibitor containing regimens.
All of these trials were more “explanatory” than “pragmatic”
[37,38], with the possible exception of STRIDE which was con-
ceived as a “strategy” trial [26], resulting in populations which
may not be representative of people with TB initiating ART in
routine practice. Five of nine trials only included people with
microbiologically confirmed TB, whereas in usual practice
many people are started on TB treatment for probable TB. All
but one trial excluded people who had previously taken and
then stopped taking ART and were newly re-engaged in HIV
care. In practice, people restarting ART after a period of not
taking ART account for a substantial proportion of ART initia-
tors [39]. Other limitations to the evidence include the lack of
data about children and pregnant women (excluded from all
trials). Adolescents were included in two trials and data com-
bined with adults. This may limit the generalizability of these
conclusions.
Importantly, many of these trials provided intensive, well-
resourced clinical follow-up as part of study protocols. Trial
participants are more likely to be highly motivated and have
more frequent monitoring than people with HIV and TB pre-
senting for care in routine national programmes. Randomized
trials of earlier ART have shown that, under programmatic
conditions, PLHIV without TB who start ART within seven
days are more likely to achieve viral suppression and more
likely to be retained in care than people who have a longer
period between HIV diagnosis and ART initiation [13,14]. It is
not known whether this is the case for PLHIV who also have
TB disease. These explanatory trials are not well suited to
address how earlier ART for people with TB would impact
retention in care under routine service conditions.
None of these trials used steroids to reduce the likelihood
and severity of IRIS, a strategy that has been shown to be
Figure 5. Forest plots showing effect estimates (absolute risk difference) of earlier versus later ART on IRIS (all CD4 counts). Summary
estimates are from random effects meta-regression models, using DerSimonian Laird method to estimate variance.
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beneficial in the PredART trial [40] and might be useful to
mitigate the effects of IRIS in people starting earlier ART. In
PredART, people started ART a median of 16 days after start-
ing TB treatment. Earlier ART initiation may promote better
integration between HIV and TB services, and unifying recom-
mendations for people at all CD4 cell counts may also have
implementation advantages, particularly given that many pro-
grammes no longer require CD4 cell counts before initiating
ART. Earlier ART is preferred by patients and is acceptable to
at least some national TB programmes (who had already rec-
ommended early ART in advance of the March 2021 WHO
recommendation). The March 2021 WHO recommendations
for earlier ART for everyone are to be welcomed.
As a final limitation, the included trials are clinically hetero-
geneous in terms of their inclusion criteria (from only people
with HIV in hospital to only ambulatory people with higher
CD4 counts), their definitions of TB (pulmonary vs. any site
and microbiologically proven only versus including clinically
diagnosed), and their outcome definitions (especially around
IRIS – as discussed above – and severe adverse events). Over-
all, death proportion varied from 3% to 16%. We used random
effects analysis to obtained pooled estimates without assum-
ing the true effect was the same in every trial. Nonetheless,
the differences between the included trials – and the differ-
ences between all of these trials and the populations of peo-
ple starting ART with TB in 2021 – mean that some caution
should be applied to interpreting these results.
This topic has previously been reviewed in peer-reviewed liter-
ature and to inform earlier WHO guidelines [7,8]. Since the previ-
ous published reviews, data from one new randomized study
have been included (RAFA trial, personal communication) and we
obtained unpublished CD4-disaggregated data that were not
previously reviewed from two trials [26,31]. We also have dis-
cussed considerations for applying results from these trials (con-
ducted from 2004 to 2014) to the newer conditions in which
ART is delivered in 2021 (with integrase inhibitors, “treat all” rec-
ommendations, and established guidelines for rapid ART in peo-
ple without TB). Although considered a key issue for the 2021
ART guidelines, this present question of when to initiate ART in
PLHIV who are not already on ART at the time of TB diagnosis
may be declining in relevance; concurrent with population
increases in ART coverage, HIV-associated TB is now more com-
monly diagnosed in people who are already on ART rather than
those who are ART na€ıve. The other important group, but not
addressed in this review, are people newly presenting for ART
assessment who do not have TB either firmly diagnosed or
excluded (i.e. people with TB symptoms who are awaiting a TB
test). The SLATE I and SLATE 2 trials indirectly addressed the
question of whether to offer same-day ART concurrent with TB
investigations or whether to defer ART to allow the investigation
to confirm or refute a TB diagnosis before starting ART.
An individual patient data meta-analysis using data from all
trials may be useful to produce more precise estimates of the
effect of earlier compared to later ART, particularly at differ-
ent CD4 cell strata.
5 | CONCLUSION
We identified nine randomized trials comparing earlier ART to
later ART in people living with HIV with TB disease who were
not taking ART. Most trials were high quality and at low risk of
bias for mortality outcomes. The trials tended to be more
explanatory than pragmatic, and so may not necessarily reflect
how ART is delivered to people with confirmed or probable TB
in programmatic settings. Earlier ART (≤4 weeks) reduced mor-
tality at one year in people with CD4 ≤50 cells/mm3 (5 trials,
risk difference 6%, 95% CI 10% to 1%, I2 0%). In people
with higher CD4 counts, there was no evidence of either bene-
fit or harm with earlier ART (≤4 weeks) (seven studies, RD 0%,
95% CI 2% to +2%, I2 23%). IRIS was more common in people
starting ART earlier, although IRIS-related mortality was uncom-
mon. IRIS was more common and increases with earlier ART
were most marked in those with CD4 <50, who were also the
group with a demonstrated mortality reduction from earlier
ART. In addition to evidence from these trials, decisions around
the timing of ART initiation should take into account contextual
information from more recent observational and trial data (e.g.
regarding the safety of integrase inhibitors in TB, improved
retention in care from earlier ART in people without TB and
reduction in incident IRIS from use of pre-emptive steroids), as
well as service users’ values and preferences, and implementa-
tion considerations for HIV programmes. For programmatic
logistical and patient preference reasons, earlier ART initiation
for everyone with TB and HIV may be preferred to later ART
initiation and this recommendation has been included in the
March 2021 WHO guidelines.
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